InternationalUSRemember you can easily switch between MIP US and MIP International at any time

MIP European Life Sciences Forum 2017 - Agenda

June 29, Le Méridien Piccadilly, London




Agenda





Delegates

Photos

Venue

Contact us

Download the brochure here



08:30 Registration

09:00 Opening remarks by James Nurton, managing editor, Managing IP

09:10 Practical planning for Brexit - key risk areas for life sciences companies

  • Parallel imports for pharma products and freedom to operate considerations
  • Trade mark protection – what will happen to existing marks & the future of non-traditional trade marks
  • Cross border injunctions
  • Customs seizures and battling counterfeits

Jeremy Blum, partner, Bristows


10:00 Second medical use patents - can a consensus be reached?

  • Solving practical problems: Warner Lambert v Actavis
  • Practically obtaining and enforcing second medical use patents (validity issues)
  • Examining evolving case law in different jurisdictions
  • Reviewing the issue of 'skinny labelling' with generics

Marianne Schaffner, partner, Dechert
David Cottam, senior director, associate general patent counsel, Teva Europe


10:50 Coffee break and networking



11:20 Supplementary protection certificates: striking the balance to protecting rights

  • Essential updates from key SPCs cases over the past year
  • Combination products judgements
  • Brexit and what this means for SPCs
  • Looking to the future: what should be changed in SPC regulation?

Paul Chapman, head of legal practice, Avidity IP
Jürgen Dressel, head of global patent litigation strategy, Novartis Pharma


12:10 Challenges and regulatory issues with digital health

  • Medical devices and sophisticated diagnostics
  • Government initiatives and legislation to help
  • What trends are we seeing in the landscape to block the launch of new diagnostics?
  • Exploring the role of IoT in digital health solutions: product liability and IP issues

Niklas Mattsson, partner, Awapatent
Anneliese Hassenbuerger
, senior patent attorney, Novartis


13:00 Lunch and networking


13:50 Coordinating UK, EU and US patent strategies: updates from the US

  • The 101 issue: Patent Eligibility in the US - what are the implications for EU patent holders?
  • Inter-partes reviews: challenges and procedural tactics to make your company IPR ready
  • Drawing comparisons between IPRs and revocation actions in Europe

Jennifer Roscetti, partner, Finnegan Henderson Farabow Garrett & Dunner
Erin Sommers, partner, Finnegan Henderson Farabow Garrett & Dunner


 14:40 Unified Patent Court - final preparations for the sunrise period

  • To what extent will the UPC be pro-patentee?
  • Taking steps towards 'troll proofing' your business
  • Alignment of UK courts and other national patent courts within the EU
  • Future forecast: will the UK remain in the system post-Brexit?

Penny Gilbert, partner, Powell Gilbert (moderator)
Francis Tierney, senior patent director, AstraZeneca
Sean Alexander, senior director, European patent counsel, Eli Lilly & Company
Peter Thomsen
, global head IP policy & senior manager IP litigation, Novartis


15:30 Coffee break and networking


15:50 Strategic considerations for dealing with patent portfolios covering biologics

  • Examining the approach of national courts
  • Using declaratory relief to deal with divisional applications
  • Related legal issues that affect the rate of entr y of biosimilars
  • Can UK courts be pragmatic and give commercial solutions? Fujifilm Kyowa Biologics v AbbVie

Luke Kempton, partner, Gowling WLG
Dean Thomas, director IP, Glenmark Pharmaceuticals


16:40 Effective litigation management strategies

  • Annual review and trends of key jurisdictions
  • Coordinating litigation across Europe in life sciences: is there a shift towards harmonisation?
  • Interplay between regulatory regimes and patent litigation

Johan Renes, partner, DLA Piper
Paul Reeskamp
, partner, DLA Piper

17:30 Close of conference


 



 

Sponsors

Avidity IP

Bristows

Dechert LLP

Finnegan

Gowling WLG

Powell Gilbert








profile

Managing IP

ManagingIP

ManagingIP profile

PTAB post-SAS: what we know and what questions remain https://t.co/KMJKfQPxFE Eight weeks on from the US Supreme Co… https://t.co/lK38MD7Kj4

Jun 21 2018 12:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

EU legal affairs committee adopts controversial copyright directive - our analysis https://t.co/ykTKfUocqj Provisio… https://t.co/699BhUHVzY

Jun 20 2018 12:42 ·  reply ·  retweet ·  favourite
ManagingIP profile

The controversial Article 13 'value gap proposal' has been adopted into the draft Directive on Copyright in the Dig… https://t.co/mbi6s6UFFP

Jun 20 2018 09:07 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


null

null null null

null null null

May 2018

Technology alters the anti-counterfeiting landscape

Ellie Mertens reveals evolving technologies are changing the counterfeiting game on both sides, as a tool for both prevention and evasion



Most read articles

Supplements